Valuation: LivaNova PLC

Market Cap 4.18B 3.74B 3.49B 3.17B 5.97B 405B 6.01B 41.91B 16.37B 206B 15.7B 15.37B 662B P/E 2026 *
19x
P/E 2027 * 22.9x
Enterprise Value 4.26B 3.8B 3.55B 3.22B 6.07B 412B 6.12B 42.66B 16.67B 209B 15.99B 15.64B 673B EV / Sales 2026 *
2.8x
EV / Sales 2027 * 2.51x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 01/03/2024
Director of Finance/CFO 56 31/10/2020
Investor Relations Contact - 01/08/2022
Director TitleAgeSince
Director/Board Member 69 19/10/2015
Chairman 74 09/06/2021
Director/Board Member 62 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.64% - - 4.18B
+0.58%-0.10%-25.78%+1.91% 171B
-1.81%-0.90%-13.04%+12.34% 109B
-1.01%+0.00%-25.41%+3.59% 106B
-1.67%-0.28%-48.26%-11.70% 75.43B
+0.28%+5.66%+2.77%+72.56% 60.54B
-0.44%+6.13%+10.95%+65.67% 53.16B
-0.08%+0.65%-6.42%-31.35% 49.07B
-1.70%-2.97%-19.23%+13.61% 39.92B
+1.09%-2.31%+27.67%+1.30% 31.81B
Average -0.12%+0.82%-10.75%+14.21% 77.31B
Weighted average by Cap. -0.17%+0.68%-16.68%+11.65%

Financials

2026 *2027 *
Net sales 1.52B 1.36B 1.27B 1.15B 2.17B 147B 2.19B 15.25B 5.96B 74.88B 5.71B 5.59B 241B 1.63B 1.46B 1.36B 1.23B 2.32B 158B 2.34B 16.33B 6.38B 80.2B 6.12B 5.99B 258B
Net income 226M 202M 189M 171M 323M 21.89B 325M 2.27B 885M 11.13B 849M 831M 35.78B 187M 167M 156M 142M 267M 18.08B 269M 1.87B 732M 9.2B 702M 687M 29.56B
Net Debt 75M 67.01M 62.52M 56.79M 107M 7.26B 108M 751M 294M 3.69B 282M 275M 11.86B -85M -75.95M -70.86M -64.36M -121M -8.22B -122M -851M -333M -4.18B -319M -312M -13.44B
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - LivaNova PLC